Akoya Biosciences, Inc. (AKYA)
NASDAQ: AKYA · Real-Time Price · USD
1.270
0.00 (0.00%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Akoya Biosciences Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Akoya Biosciences stock have an average target of 2.99, with a low estimate of 1.65 and a high estimate of 5.00. The average target predicts an increase of 135.43% from the current stock price of 1.27.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Akoya Biosciences stock from 7 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 5 | 5 | 5 | 5 | 5 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold Maintains $2.4 → $1.65 | Hold | Maintains | $2.4 → $1.65 | +29.92% | Apr 14, 2025 |
| Stephens & Co. | Stephens & Co. | Buy → Hold Downgrades $3.5 → $1.8 | Buy → Hold | Downgrades | $3.5 → $1.8 | +41.73% | Mar 25, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $3.5 | Buy | Reiterates | $3.5 | +175.59% | Mar 18, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $4 → $3 | Buy | Reiterates | $4 → $3 | +136.22% | Nov 19, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy → Hold Downgrades $7 → $5 | Strong Buy → Hold | Downgrades | $7 → $5 | +293.70% | Nov 15, 2024 |
Financial Forecast
Revenue This Year
93.06M
from 81.67M
Increased by 13.94%
Revenue Next Year
106.53M
from 93.06M
Increased by 14.48%
EPS This Year
-0.65
from -1.12
EPS Next Year
-0.50
from -0.65
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 99.2M | 118.6M | 134.7M | ||
| Avg | 93.1M | 106.5M | 113.9M | ||
| Low | 85.8M | 90.7M | 93.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.5% | 27.4% | 26.5% | ||
| Avg | 13.9% | 14.5% | 6.9% | ||
| Low | 5.1% | -2.5% | -12.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.46 | -0.36 | -0.48 | ||
| Avg | -0.65 | -0.50 | -0.50 | ||
| Low | -0.74 | -0.65 | -0.50 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.